4//SEC Filing
FOEHR MATTHEW W 4
Accession 0001193125-26-003109
CIK 0001607678other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 8:25 PM ET
Size
12.1 KB
Accession
0001193125-26-003109
Insider Transaction Report
Form 4
FOEHR MATTHEW W
Director
Transactions
- Exercise/Conversion
Common Stock, par value $0.00001 per share
2026-01-02$3.33/sh+16,000$53,280→ 148,036 total - Sale
Common Stock, par value $0.00001 per share
2026-01-02$35.11/sh−16,000$561,694→ 132,036 total - Award
Common Stock, par value $0.00001 per share
2026-01-02+3,150→ 135,186 total - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-02−16,000→ 0 totalExercise: $3.33From: 2017-01-04Exp: 2026-01-04→ Common Stock (16,000 underlying) - Award
Stock Option (Right to Buy)
2026-01-02+20,400→ 20,400 totalExercise: $35.42From: 2027-01-02Exp: 2036-01-02→ Common Stock (20,400 underlying)
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.
Documents
Issuer
Viking Therapeutics, Inc.
CIK 0001607678
Entity typeother
Related Parties
1- filerCIK 0001237556
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 8:25 PM ET
- Size
- 12.1 KB